Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tehran University of Medical Sciences
Pioglitazone as a Ppar-gamma agonist is an anti diabetic drug. It was also shown that, it has certain anti inflammatory and neuro-protective effects. In recent years it has been proposed that Ppar-gamma agonists may have effects on mood and cognition. In animal studies and in one human case report as well as a pilot study on human subjects these drugs improved symptoms of depression. A randomized controlled and double blind design will provide further evidence for the efficacy of these drugs in major depressive disorder.
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Major depressive disorder based on DSM-IV TR criteria
Age 18-50
Hamilton Depression Rating scale \>=22
Signing the informed consent form
Citalopram be the drug of choice for the patient irrespective of other eligibility criteria
You may not be if
Problems in other Axes
Pregnancy and lactation
Serious or life threatening disease
taking other antidepressant in the recent month or Electroconvulsive shock in the recent two months, and taking other psychotropic agents
Diabetes controlled with drugs or insulin (patients with only lifestyle interventions will be included), Liver disease, Congestive heart failure Class III and IV
Metabolic syndrome
Clareo Health | Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder
